On October 17, 2025, Amgen and AstraZeneca announced that the FDA has approved an additional indication for TEZSPIRE (tezepelumab-ekko) for the add-on maintenance treatment of inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) in adult and pediatric patients aged 12 years and older. TEZSPIRE is the first biologic the FDA has approved for the treatment
Latest Post
More Posts
Genentech Files First Pertuzumab BPCIA Complaint Against Shanghai Henlius and Organon
Update on Regeneron’s Supplemental BLA for EYLEA HD
FDA Approves Celltrion’s STEQEYMA (ustekinumab-stba)
European Commission Approves Samsung Bioepis and Biogen’s Aflibercept Biosimilar
Accord Biopharma Announces FDA Approval of IMULDOSA (ustekinumab-srlf)
FDA Seeks Input on Biosimilar Product Development Guidance
FDA Approves Moderna’s mRESVIA Vaccine
FDA Launches Support for Clinical Trials Advancing Rare Disease Therapeutics (START) Pilot Program
Alvotech Announces More Settlements and Expected Launch Dates Regarding Biosimilar to STELARA (ustekinumab), AVT04
Subscribe: Subscribe via RSS
Blogs
Firm/Org